nVerses Capital LLC Invests $51,000 in Alector, Inc. (NASDAQ:ALEC)

nVerses Capital LLC purchased a new stake in Alector, Inc. (NASDAQ:ALEC) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,000 shares of the company’s stock, valued at approximately $51,000.

A number of other large investors have also recently bought and sold shares of ALEC. Allspring Global Investments Holdings LLC acquired a new position in Alector in the first quarter valued at $40,000. Swiss National Bank grew its holdings in shares of Alector by 6.5% during the first quarter. Swiss National Bank now owns 131,900 shares of the company’s stock worth $794,000 after buying an additional 8,000 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Alector in the 1st quarter valued at about $760,000. Russell Investments Group Ltd. raised its stake in Alector by 9.9% during the 1st quarter. Russell Investments Group Ltd. now owns 78,348 shares of the company’s stock valued at $472,000 after acquiring an additional 7,066 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in Alector by 24.1% during the 1st quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock worth $119,000 after acquiring an additional 3,827 shares during the period. Institutional investors and hedge funds own 85.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a report on Tuesday, September 17th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Alector currently has an average rating of “Buy” and an average price target of $17.75.

Insider Transactions at Alector

In related news, CFO Marc Grasso sold 7,297 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $35,609.36. Following the completion of the sale, the chief financial officer now owns 130,740 shares in the company, valued at $638,011.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $129,315.12. Following the sale, the chief executive officer now directly owns 1,948,746 shares in the company, valued at approximately $9,509,880.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Marc Grasso sold 7,297 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $35,609.36. Following the completion of the transaction, the chief financial officer now owns 130,740 shares of the company’s stock, valued at approximately $638,011.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,222 shares of company stock valued at $286,013 in the last ninety days. 9.10% of the stock is currently owned by company insiders.

Alector Trading Down 7.6 %

NASDAQ ALEC opened at $4.61 on Tuesday. The stock has a market capitalization of $444.33 million, a price-to-earnings ratio of -3.34 and a beta of 0.68. The business’s 50 day moving average is $5.11 and its two-hundred day moving average is $5.17. Alector, Inc. has a 12-month low of $3.66 and a 12-month high of $8.90.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. The firm had revenue of $15.08 million for the quarter, compared to analyst estimates of $16.04 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. Equities analysts forecast that Alector, Inc. will post -1.92 earnings per share for the current fiscal year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.